Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV ulimorelin after partial bowel resection for postoperative ileus
2010-023229-38Phase 3Completed
- Sponsor
- Tranzyme Pharma
- Start
- Nov 2010
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ulimorelin in postoperative ileus (POI) (3 arms), sponsored by Tranzyme Pharma. Primary endpoint: Time to recovery of gastrointestinal function (GI2). Started Nov 2010; status: completed.
02
Drugs
ulimorelin
03
Conditions
postoperative ileus (POI)
Beyond the preview
Go deeper on 2010-023229-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023229-38.